UNCY Unicycive Therapeutics Inc

Price (delayed)

$7.44

Market cap

$198.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.21

Enterprise value

$162.09M

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 69
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic ...

Highlights
The equity has increased by 25% since the previous quarter
UNCY's quick ratio has soared by 73% year-on-year but it is down by 6% since the previous quarter
The company's EPS fell by 32% QoQ but it rose by 2.2% YoY
UNCY's net income has dropped by 163% year-on-year and by 50% since the previous quarter
UNCY's debt is up by 49% year-on-year

Key stats

What are the main financial stats of UNCY

UNCY stock price

How has the Unicycive Therapeutics stock price performed over time
Intraday
3.33%
1 week
5.98%
1 month
-6.77%
1 year
-4%
YTD
28.94%
QTD
13.07%

Financial performance

How have Unicycive Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.97M
Net income
-$39.95M
Gross margin
N/A
Net margin
N/A
UNCY's net income has dropped by 163% year-on-year and by 50% since the previous quarter
The company's operating income rose by 3% YoY

Price vs fundamentals

How does UNCY's price correlate with its fundamentals

Growth

What is Unicycive Therapeutics's growth rate over time

Valuation

What is Unicycive Therapeutics stock price valuation
P/E
N/A
P/B
4.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 32% QoQ but it rose by 2.2% YoY
The P/B is 38% higher than the last 4 quarters average of 3.5
The equity has increased by 25% since the previous quarter

Efficiency

How efficient is Unicycive Therapeutics business performance
Unicycive Therapeutics's ROE has soared by 53% YoY but it has decreased by 18% from the previous quarter
UNCY's ROA is down by 34% YoY and by 22% QoQ

Dividends

What is UNCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UNCY.

Financial health

How did Unicycive Therapeutics financials performed over time
Unicycive Therapeutics's total assets is 141% more than its total liabilities
Unicycive Therapeutics's total assets has soared by 130% YoY and by 31% from the previous quarter
UNCY's quick ratio has soared by 73% year-on-year but it is down by 6% since the previous quarter
UNCY's debt is 98% smaller than its equity
Unicycive Therapeutics's debt to equity has shrunk by 60% YoY
UNCY's debt is up by 49% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.